Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALB | P02768 | 3/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.47 |
| ▸ | GNPAT | O15228 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22769501 | 1.00 | FOLH1 (0.55) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| SCHEMBL29550463 | 1.00 | FOLH1 (0.55) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| SCHEMBL6026003 | 0.95 | FOLH1 (0.49) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| SCHEMBL446929 | 0.95 | FOLH1 (0.49) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| SCHEMBL468901 | 0.95 | FOLH1 (0.49) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| SCHEMBL30526285 | 0.95 | FOLH1 (0.49) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| Acetic Acid SCHEMBL28406175 | 0.94 | FOLH1 (0.48) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| SCHEMBL9438405 | 0.94 | FOLH1 (0.48) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| Water SCHEMBL29401510 | 0.94 | FOLH1 (0.48) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 | |
| Hydrochloric Acid SCHEMBL4422480 | 0.94 | FOLH1 (0.48) | FOLH1SMN1; SMN2ALBSIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | claimed |
| EP-3039068-B1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MAT INC (US) | 2020-12-16 | — | — | EP | claimed |
| US-9914809-B2 | Moisture curable composition with amino acids | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2018-03-13 | — | — | US | claimed |
| US-20160200880-A1 | MOISTURE CURABLE COMPOSITION WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MATERIALS INC. | 2016-07-14 | — | — | US | claimed |
| EP-3039068-A1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | Momentive Performance Materials Inc. (US) | 2016-07-06 | — | — | EP | claimed |
| WO-2015031712-A1 | MOISTURE CURABLE COMPOUND WITH AMINO ACIDS | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2015-03-05 | — | — | WO | claimed |
| US-RE44302-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-06-18 | — | — | US | claimed |
| EP-1060739-B1 | Slimming cosmetic composition containing L-arginine or a derivative thereof | EXSYMOL SA (MC) | 2013-04-03 | — | — | EP | claimed |
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | claimed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-RE41278-E1 | N-acetyl aldosamines and related N-acetyl compounds, and their topical use | TRISTRATA, INC. | 2010-04-27 | — | — | US | claimed |
| EP-2080504-A2 | Topical composition comprising n-acetylaldosamines or n-acetylamino acids | Yu, Ruey J. (US) | 2009-07-22 | — | — | EP | claimed |
| EP-1639994-A2 | Topical composition comprising N-acetylaldosamines or N-acetylamino acids | Yu, Ruey J., Dr. (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | FOLH1 181/4885SMN1; SMN2 453/4885ALB 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.